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Abstract
There is no standard third-line or further systemic treatment for patients with inoperable locoregionally advanced recurrent or
metastatic nasopharyngeal carcinoma (NPC). Metronomic oral cyclophosphamide provides an acceptable and cheap option for
these heavily pretreated patients who had limited choices. We conducted a prospective phase II single-arm open-label study of
metronomic oral cyclophosphamide. Patients with locoregionally advanced recurrent inoperable (rT3/T4, rN2-N3b) or metastatic
(rM1) NPCwho had Eastern Cooperative Oncology Group (ECOG) performance status (PS) (0–2) and had progressed after at least 2
lines of palliative systemic chemotherapy were eligible. They received oral cyclophosphamide between 50 and 150mg once daily until
progressive disease or unacceptable toxicity. Objective response rate (ORR), disease control rate (DCR), biochemical response (two
consecutive declines of plasma EBV DNA after treatment), progression-free survival (PFS), overall survival (OS), and safety proﬁles
were evaluated. A total of 56 patients were recruited. Thirty-three, 13, 6, 3, and 1 patients received cyclophosphamide as 3rd, 4th,
5th, 6th, and 7th line of therapy respectively. After amedian follow-up of 9.95months (range 1.76–59.51months), the ORRwas 8.9%
and the DCR was 57.1%. The median PFS and OS were 4.47 and 9.20 months, respectively. Those with PS 1 had longer median
PFS (5.49 months) compared to those with PS 2 (3.75 months, P= .011). Besides, those who had locoregionally recurrent disease
had better PFS (8.97 months, 95% CI, 0.53–17.41 months) compared to those who had distant metastases (4.14 months, 95% CI,
2.53–5.75 months, P= .020). Multivariable analysis revealed that PS 1 (vs 2) (P= .020) and locoregional recurrence (vs metastasis)
(P= .029) were the only signiﬁcant independent prognostic factors of PFS. Around 16 (28.6%) patients developed grade ≥3 adverse
events, including malaise (5.4%), hematological (8.9%), gastrointestinal (3.6%), feverish (3.6%), and hemorrhagic (1.8%) events. The
median cost of the whole drug treatment was 51.65 US dollars (USD) (range 4.15–142.75 USD) (1 USD=7.8 HK dollars [HKD]).
Metronomic oral cyclophosphamide is an acceptable third-line or beyond systemic therapy for locoregionally advanced recurrent or
metastatic NPC with acceptable toxicity and limited ﬁnancial burden.
Abbreviations: ALT = alanine aminotransferase, AST = aspartate aminotransferase, CT = computed tomography, CTCAE =
Common Terminology Criteria for Adverse Events, DCR = disease control rate, DNA = deoxyribonucleic acid, EBV = Epstein–Barr
virus, ECOG = Eastern Cooperative Oncology Group, EGFR = epidermal growth factor receptor, HKD = Hong Kong dollars, NPC =
nasopharyngeal carcinoma, ORR = objective response rate, OS = overall survival, PD-1 = programmed cell death-1, PFS =
progression-free survival, PS = performance status, RECIST = Response Evaluation Criteria for Solid Tumors, USD = US dollars,
ULN = upper normal limit, VEGF = vascular endothelial growth factor.
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11. Introduction
Undifferentiated nasopharyngeal carcinoma (NPC) is an endemic
malignancy with a high incidence in Southern China, Hong
Kong, Taiwan, and Singapore.[1] Radiotherapy is the mainstay of
treatment for early stage NPC, while concurrent chemoradiation
with or without adjunct chemotherapy is indicated for locore-
gionally advanced disease.[2] Nevertheless, about 30% of cases
relapse locoregionally or distantly, despite intensive deﬁnitive
treatment.[3] Salvage surgery or second-course radical radiother-
apy with or without chemotherapy can achieve durable disease
control and promising survival for locoregional relapse.[4,5]
However for those with locoregionally advanced recurrent
disease who had received 2 courses of radical radiotherapy or
those with distant metastases, systemic chemotherapy would be
the only treatment of choice. Platinum-based doublet chemo-
therapy including cisplatin with 5-ﬂuorouracil, capecitabine,
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treatment due to its long-standing history and experience,
especially for chemo-naïve patients.[6] For second-line treatment
of metastasis, whether platinum-based chemotherapy was given
previously is a consideration. For patients treated with platinum-
based chemotherapy, subsequent treatment depends on perfor-
mance status, toxicity, and the time interval to recurrence after
previous platinum-based regimen. Re-challenge with cisplatin
and 5-ﬂuorouracil can be considered in patients who enjoyed a
good initial response to the same regimen with an intervening
disease-free period of more than 1 year. Carboplatin may be an
acceptable alternative, producing similar responses and outcomes
when cisplatin is contraindicated, though it generally brings more
hematological toxicities. For patients who fail platinum and 5-
ﬂuorouracil or whose diseases relapse within a year of such
regimen, second-line treatment including gemcitabine, capecita-
bine, or taxanes with or without platinum can be considered.
However, so far there has been no recognized standard third-line
systemic treatment. Metronomic oral chemotherapy may provide
an ideal choice to patients treated in this setting by shifting the
targets from tumor cells to tumor vasculature so as to reduce the
chance of drug resistance as well as offering a relatively low
toxicity proﬁle to them who have been signiﬁcantly jeopardized
by the long-term complications brought by prior courses of
radiation therapy, surgery and chemotherapy.[7–9] We presented
the results of a phase II single-institution trial on the use of
metronomic open-label oral cyclophosphamide as third-line
treatment or beyond in patients with inoperable locoregionally
advanced recurrent or metastatic NPC who had failed at least 2
lines of prior systemic chemotherapy.2. Methods and materials
2.1. Patients
The study was approved by local institutional review board
(Institutional Review Board of the University of Hong Kong/
Hospital Authority West Cluster) before commencement. It was
also registered with clinicaltrials.gov (NCT02794077) and
conducted according to Declaration of Helsinki with good
clinical practice. The study recruitment period started from
January 2008 till November 2015. Patients with inoperable
locoregionally advanced recurrent NPC of undifferentiated type
beyond curative surgical resection or second and subsequent
courses of radical radiotherapy or metastatic disease who all had
received at least 2 lines of palliative systemic chemotherapy (of
which one of them must be platinum-based chemotherapy) were
eligible to participate into this study. All of them must have
adequate hematological (absolute neutrophil count ≥1.5109/L;
hemoglobin ≥9.0g/dL and platelet ≥100109/L), renal (serum
creatinine1.5upper normal limit [ULN]) and hepatic reserves
(serum bilirubin 1.5ULN; alanine aminotransferase (ALT)
and aspartate aminotransferase (AST) 3ULN for patients
without liver metastases or 5ULN for those with liver
metastases). Patients whose Eastern Cooperative Oncology
Group (ECOG) performance status (PS) was 3 or above were
excluded. After written informed consent, they had baseline
investigations including serum hematology, serum renal and liver
biochemistry, plasma Epstein–Barr virus (EBV) deoxyribonucleic
acid (DNA), as well as contrast-enhanced computed tomography
(CT) scan of the head and neck, thorax and abdomen. Then they
received open-label oral cyclophosphamide at 50 to 150mg daily
continuously until radiologically documented progressive dis-2ease, unacceptable toxicities or patient withdrawal. The starting
dose of cyclophosphamide was determined by the treating
oncologists based on patients’ performance status and their
disease status. Serum hematology and biochemistry were
monitored at least once every 3 weeks to monitor any
treatment-related hematological and biochemical toxicities. As
cyclophosphamide was in the form of 50mg tablet, dose
escalation or reduction would be a 50-mg-increment or
decrement, respectively. For those starting at 50mg daily or
100mg daily, dose escalation to one or two dose levels up until
150mg daily was allowed if they do not experience any
treatment-related grade ≥2 events (based on Common Termi-
nology Criteria for Adverse Events [CTCAE] version 3.0) after
starting cyclophosphamide for 2 weeks. For those who developed
grade ≥3 treatment-related adverse events, cyclophosphamide
would be withheld until it returned to grade1. They would then
receive cyclophosphamide one dose level down upon resuming it.
The lowest acceptable daily dose was 50mg daily. They would
also be permanently discontinued from cyclophosphamide if the
adverse event(s) did not return to grade 1 within 21 days of
treatment interruption. For those who interrupted cyclophos-
phamide for more than 21 days for whatever reasons, they would
be permanently discontinued from the study as well. Serial blood
test for plasma EBV DNA was monitored every 9 weeks while
interval contrast-enhanced computed tomography (CT) scan of
the head and neck, thorax and abdomen followed by interval
scans were performed every 3 months for every recruited patient
after commencement of study medication until progressive
disease. Best objective response was determined by Response
Evaluation Criteria for Solid Tumors (RECIST) 1.1.[10]2.2. Statistical analysis
The primary study endpoint was progression-free survival (PFS),
calculated from the date of start of cyclophosphamide to the date
of radiologically documented progressive disease or the date of
death. Secondary endpoints include objective response rate
(ORR), disease control rate (DCR), biochemical PFS (calculated
from the date of start of cyclophosphamide to the date of the
second consecutive elevation of plasma EBV DNA from nadir
after starting cyclophosphamide), overall survival (OS) (calcu-
lated from the date of start of cyclophosphamide to the date of
death from any cause) and toxicity proﬁle. Nonparametric
variables were compared by Mann Whitney-U tests. Kaplan–
Meier methods were employed for calculation of PFS and OS.
Log-rank tests were employed for subgroup survival compar-
isons. Cox proportional hazard models with univariable and
multivariable analyses were performed for prognostic factors of
PFS and OS. Statistical signiﬁcance was deﬁned as P< .05 (two-
sided). All statistical analyses were performed by Statistical
Package for Social Sciences version 22. Data cut-off was
performed on 1st May 2016.3. Results
3.1. Patient characteristics
A total of 56 patients were recruited into this study with the
baseline demographics shown in Table 1. Eleven (19.6%)
patients had incurable locoregionally recurrent disease while
45 (80.4%) patients had distant metastases before cyclophos-
phamide commencement. Sixteen and 37 (66.1%) had ECOG PS
1 and 2, respectively. Thirty-three, 13, 6, 3, and 1 patients
Table 1
Patient characteristics.
n=56 (%)
Median age in years (range) 51 (22–76)
Sex (M/F) 44 (78.6) /12 (21.4)
ECOG PS
1 19 (33.9)
2 37 (66.1)
Disease status
Locoregionally advanced recurrence 11 (19.6)
Distant metastases 45 (80.4)
Lung 25 (44.6)
Bone 32 (57.1)
Liver 23 (41.1)
Skin 2 (3.6)
Distant 15 (26.8)
Number of involved distant sites
1 12 (21.4)
2 22 (39.3)
3 11 (19.6)
4 2 (3.6)
Number of lines of prior systemic chemotherapy
2 33 (58.9)
3 13 (23.2)
4 6 (10.7)
5 3 (5.4)
6 1 (1.8)
Median baseline plasma EBV DNA in copies/mL (range) 19,000 (20–98,250,000)
EBV DNA=Epstein–Barr virus deoxyribonucleic acid, ECOG=Eastern Cooperative Oncology Group,
F= female, M=male, PS=performance status.
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seventh line of therapy, respectively. One (1.8%), 17 (30.4%),
and 38 (67.9%) patients received 50mg, 100mg, and 150mg
daily as the starting dose.3.2. Treatment efﬁcacy and cost
After a median follow-up duration of 9.95 months (range 1.76–
59.51 months), 5 patients derived an objective response, giving
an ORR of 8.9%. The DCR was 57.1%, observed in 32 patients.
The median duration of therapy was 2.86 months (range 0.46–
15.84 months). The median PFS for the whole study population
was 4.47 months (95% conﬁdence interval [CI], 3.18–5.76
months) (Fig. 1A). Those with ECOG PS 1 had a longer median
PFS (5.49 months, 95% CI, 0.42–10.56 months) compared to
those with ECOG PS 2 (3.75 months, 95% CI, 3.05–4.45
months, P= .011) (Fig. 1B). In addition, those who had
locoregionally advanced recurrent disease had better median
PFS (8.97 months, 95% CI, 0.53–17.41 months) compared to
those who suffered from distant metastases (4.14 months, 95%
CI, 2.53–5.75 months, P= .020) (Fig. 1C). The biochemical PFS
for the whole study population was 3.75 months (95% CI 2.11–
5.38 months) (Fig. 2A). Those who had better PS 1 enjoyed a
longer median biochemical PFS (5.45 months, 95% CI, 4.57–
6.34 months) than patients whose ECOG PS was 2 (3.42 months,
95% CI, 1.97–4.87, P= .007) (Fig. 2B). Similarly, those who
had locoregionally advanced recurrent disease enjoyed longer
biochemical PFS (8.97 months, 95% CI, 3.01–14.92 months) as
compared to those who had distant metastases (3.42 months,
95% CI, 2.01–4.83 months; P= .004) (Fig. 2C).
One patient is still receiving cyclosphosphamide with stable
disease at the time of submission of this publication. The cost of3each 50mg tablet cyclophosphamide was 0.30 US dollars (USD)
(as onMay 31st, 2016, assuming 1 USD=7.8Hong Kong dollars
[HKD]) and thus the median cost of the whole drug treatment
was 25.77 USD (range 4.15–142.75).3.3. Univariable and multivariable analyses for prognostic
factors of PFS and biochemical PFS
Univariable and multivariable analysis for the prognostic factors
of PFS and biochemical PFS were displayed in Table 2.
Multivariable analysis revealed that ECOG PS 1 (vs 2)
(P= .020) and locoregionally advanced recurrence (vs metastasis)
(P= .029) were the only signiﬁcant independent prognostic
factors of PFS. They were also the only signiﬁcant independent
prognostic factors for biochemical PFS (P= .014 and P= .005,
respectively).3.4. Safety proﬁles
Three (5.4%) patients had dose escalation from 100 to 150mg
daily in view of good drug tolerability and absence of acute grade
2 adverse events after 2 weeks of drug therapy. However, 1 of
them had subsequent dose reduction to 100mg daily because
persistent grade 3 malaise.
Adverse events were observed in 34 (60.7%) patients (Table 3).
Sixteen (28.6%) patients developed grade ≥3 adverse events,
including malaise (5.4%), hematological (8.9%), gastrointestinal
(3.6%) and feverish (3.6%) and hemorrhagic (1.8%) events.
Treatment interruption secondary to adverse events were
observed in 25 (44.6%) patients. Dose reduction was necessary
in 23 (41.1%) patients because of these grade ≥3 adverse events.
All but 3 patients had only one level dose reduction due to their
adverse events. Another 2 (3.6%) patients were permanently
discontinued from cyclophosphamide because of persistent
unresolving grade 3 malaise for more than 3 weeks, though it
subsided completely without sequelae after cyclophosphamide
termination. One patient died of sudden massive epistaxis due to
bleeding recurrent tumor despite an initial response. There was
no treatment-related fatality.3.5. Postcyclophosphamide systemic treatment
Twenty (35.7%) patients received further systemic treatment
after progression to cyclophosphamide. The lines of further
systemic treatment ranged from 1 to 9 (median 2). The median
OS for the whole study population was 9.20 months (95% CI,
6.32–12.08 months) (Fig. 3A). Those with locoregionally
advanced recurrence (14.49 months, 95% CI, 10.56–18.42
months) tended to survive longer than those with distant
metastasis (8.35 months, 95% CI, 5.89–10.80; P= .099). Those
who received further systemic treatment enjoyed a longer median
OS (15.97 months, 95% CI 11.72–20.22 months) than those
who did not (5.98 months, 95%CI, 4.92–7.04 months, P< .001)
(Fig. 3B). The number of lines of postcyclophosphamide systemic
treatment was prognostic of OS in univariable (P= .001) and
multivariable analysis (P< .001). (Supplementary Table 1, http://
links.lww.com/MD/B653).
4. Discussion
The survival outcomes of patients with previously untreated NPC
have improved steadily for the past few decades, owing to
signiﬁcant contributions by use of concurrent chemoradiation
Figure 1. (A) Kaplan–Meier curve showing the progression-free survival of the whole study population. (B) Kaplan–Meier curves showing the progression-free
survival of the study patients stratiﬁed by performance status. (B) Kaplan–Meier curves showing the progression-free survival of the study patients stratiﬁed by
disease status of recurrence versus distant metastasis.
Lee et al. Medicine (2017) 96:15 Medicinewith or without adjunct chemotherapy and the implementation
of precision radiation techniques including intensity-modulated
radiation therapy. Nevertheless, still between 5% and 15% of
these patients will eventually develop locoregional failure and
15% to 30% will fail distantly. A vast majority of these patients
with locoregional recurrence still have to resort to palliative
systemic chemotherapy after failure to salvage surgery or re-
irradiation. Systemic chemotherapy remains the mainstay of
treatment for these patients with inoperable locoregionally
advanced recurrent and those metastatic NPC. For chemo-naïve
patients, monotherapy may be only recommended for those
patients with suboptimal PS as the response rate and survival
outcomes are less than satisfactory (Supplementary Table 2,
http://links.lww.com/MD/B653).[11–23] Platinum doublet chemo-
therapy is still recommended as the ﬁrst-line treatment for those
who have satisfactory PS, owing to the platinum sensitivity and
long-standing history in clinical use (Supplementary Table 3,
http://links.lww.com/MD/B653).[12,24–52] In particular, cisplatin
and 5-ﬂuorouracil is the most popular selection due to its
widespread use in head and neck squamous cell carcinoma and4acceptable toxicity. Recently, newer agents including paclitaxel,
docetaxel, gemcitabine and capecitabine have gradually replaced
5-ﬂuorouracil as the companion of cisplatin, so as to avoid
prolonged hospitalization for 5-ﬂuorouracil infusion.Meanwhile
newer platinum compounds including carboplatin, oxaliplatin,
nedaplatin, and lobaplatin (both manufactured in China) were
tested as alternative to cisplatin for their more favorable toxicity
proﬁle of nephrotoxicity and neurotoxicity. Nevertheless,
cisplatin is still preferred to other platinum compounds as 2
old randomized-controlled trials on head and neck cancers
showed a superior response rate and survival outcomes with
cisplatin. Polychemotherapy, though theoretically more potent, is
also more toxic and distressing to patients and thus not routinely
recommended (Supplementary Table 4, http://links.lww.com/
MD/B653).[53–64] Choice of second-line systemic chemotherapy
heavily depends on the drugs used in the ﬁrst line. For patients
treated with prior platinum-based chemotherapy, subsequent
treatment depends on performance status, toxicity, and the
interval to recurrence after the last platinum-based regimen. Re-
challenge with cisplatin and 5-ﬂuorouracil can be considered in
Figure 2. (A) Kaplan–Meir curve showing the biochemical progression-free survival of the whole study population. (B) Kaplan–Meier curves showing the
biochemical progression-free survival of the study patients stratiﬁed by performance status. (C) Kaplan–Meier curves showing the biochemical progression-free
survival of the study patients stratiﬁed by disease status of recurrence versus distant metastasis.
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with a relapse-free period of more than 1 year. Carboplatin is an
acceptable substitute producing similar responses and outcomes
when cisplatin is contraindicated, though it generally gives rise to
more hematological toxicities. For patients who fail platinum andTable 2
Univariable and multivariable analyses for prognostic factors of prog
Progression-free sur
Univariable analysis Multi
HR 95% CI P HR
Age 1.002 0.970–1.035 .915
Sex (male as reference) 1.486 0.475–2.963 .261
ECOG PS (1 as reference) 0.445 0.234–0.847 .014 0.480
Recurrence (reference) vs. metastasis 0.426 0.204–0.893 .024 0.462
Baseline plasma EBV DNA 1.589 0.819–2.871 .715
Number of lines of prior systemic chemotherapy 1.119 0.840–1.492 .442
Number of sites of metastasis 1.214 0.830–1.775 .317
∗
Only covariates found signiﬁcant in univariable analysis (P< .1) were analyzed in multivariable analysi
CI= conﬁdence interval, DNA=deoxyribonucleic acid, EBV=Epstein–Barr virus, ECOG=Eastern Coope
55-ﬂuorouracil or whose disease relapse within a year of such a
regimen, second-line treatment including gemcitabine, capecita-
bine, or taxanes with or without platinum is generally
recommended. There is no standard third-line treatment as
virtually no publication has addressed this issue. Patients afterression-free survival and biochemical progression-free survival.
vival Biochemical progression-free survival
variable analysis
∗
Univariable Analysis Multivariable Analysis
∗
95% CI P HR 95% CI P HR 95% CI P
ND 1.016 0.981–1.052 .367 ND
ND 1.308 0.663–2.580 .438 ND
0.252–0.894 .020 0.419 0.218–0.805 .009 0.456 0.237–0.878 .014
0.220–0.913 .029 0.322 0.144–0.720 .006 0.348 0.155–0.784 .005
ND 1.602 0.797–2.763 .710 ND
ND 0.994 0.742–1.331 .967 ND
ND 1.563 0.993–2.458 .053 1.571 0.989–2.469 .071
s.
rative Oncology Group; HR=hazard ratio, ND=not done, PS=performance status.
Table 3
Toxicity proﬁles.
All grades (%) Grade ≥3 (%)
Malaise 7 (12.5) 3 (5.4)
Neutropenia 20 (35.7) 5 (8.9)
Thrombocytopenia 2 (3.6) 0 (0)
Vomiting 4 (7.1) 2 (3.6)
Fever 5 (8.9) 2 (3.6)
Pneumonia 3 (5.4) 3 (5.4)
Elevated liver transaminases 1 (1.8) 0 (0)
Epistaxis 1 (1.8) 1 (1.8)
Herpes zoster infection 1 (1.8) 0 (0)
All 34 (60.7) 16 (28.6)
Lee et al. Medicine (2017) 96:15 Medicinefailure to 2 prior lines of treatment are generally physically
compromised, as brought by the permanent platinum-related side
effects including nephrotoxicity, neurotoxicity and immunosup-
pression. However, the relatively slow disease tempo of NPC as
compared to other common solid malignancies can be distressing
and torturing to patients for quite a while secondary to the
intracranial symptoms of headache, facial paresthesia, diplopia
by the locally advanced recurrence and the emerging side effects
after salvage surgery and 2nd course radiotherapy including
trismus, temporal lobe necrosis, osteoradionecrosis, poor oral
hygiene, dysphagia, etc.
Oral metronomic chemotherapy may provide promising
disease control and symptom relief for these heavily pretreated
patients, while maintaining a relatively reasonable quality of life
with less devastating toxicities compared to the intravenous
drugs. Metronomic chemotherapy was ﬁrst described by
Hanahan et al,[65] which refers to the close and regular
administration of chemotherapy for a long period of time
without an intended drug-free interval. This idea was developed
to overcome the drug resistance by shifting the therapeutic target
from the tumor cells to the tumor vasculature.[9,66] Standard
chemotherapy cycles and schedules only cause meager endothe-
lial cell damage. These cells can easily repair during the rest
periods of chemotherapy and thus continue to support growth of
tumor cells leading to eventually drug resistance. The more
compact administration of low-dose chemotherapy may soundFigure 3. (A) Kaplan–Meier curve showing the overall survival of the whole study
patients stratiﬁed by the use of further systemic treatment after cyclophosphamid
6more effective against tumor vasculature while giving less
toxicities to patients and avoiding unnecessary drug interruption.
In fact, Browder and Kerbel ﬁrst highlighted the anti-angiogenic
phenomenon after metronomic scheduling of cyclophosphamide,
more effective than the conventional scheduling of chemotherapy
in overcoming drug resistance in breast cancer cell lines.[67,68]
Other plausible mechanisms of metronomic chemotherapy
include activation of immunity through reduction of regulatory
T-cells and dendritic cell maturation and direct tumor cell kill.
Previous studies have clearly demonstrated the efﬁcacy and safety
of oral metronomic cyclophosphamide, used either as mono-
therapy, or in combination with other chemotherapeutic agents
or targeted drugs in various types of solid malignancies including
breast cancer, prostate cancer, colorectal cancer, ovarian cancer
and melanoma, giving an objective response rate between 5%
and 60% and time to progression between 1.8 and 7.2
months.[69–73] Perhaps and more important to patients, cyclo-
phosphamide even without ﬁnancial reimbursement is not costly
to patients who take it for a prolonged time period.
Recently targeted therapy including antiepidermal growth
factor receptor (EGFR), antivascular endothelial growth factor
(VEGF) and multikinase inhibitor becomes an alternative option
for those who are refractory or refuses chemotherapy.[74–83]
Most of them, however, only provide a modest and short
response. In particular, sorafenib and sunitinib can give rise to
serious and fatal hemorrhage events.[81] In addition, immuno-
therapy has also evolved gradually in the treatment of recurrent/
metastatic NPC. The immunological approach encompasses
various strategies namely EBV-directed adoptive and active
immunotherapy, administration of antibodies, induction of EBV
lytic cycle, and immune checkpoint inhibition.[84–92] Though
preliminary results are encouraging and safe, these approaches
are still experimental and only limited to tertiary institutions with
expertise and comprehensive laboratory infrastructure. Immune
checkpoint inhibitors against programmed cell death-1 (PD-1)
have been recently extensively investigated for recurrent/
metastatic NPC. A phase Ib study demonstrated that pembro-
lizumab gave an OR rate of 22.2% and a disease control rate of
77.8% in 27 heavily pretreated patients with advanced NPC.[93]
Phase II trials have been ongoing to further investigate the efﬁcacy
and safety of pembrolizumab (NCT02611960) and nivolumab
(NCT02339558) as second or subsequent line treatment.population. (B) Kaplan–Meier curves showing the overall survival of the study
e.
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Lee et al. Medicine (2017) 96:15 www.md-journal.comIn summary, metronomic oral cyclosphosphamide is an
acceptable 3rd line systemic treatment for inoperable recurrent
or metastatic NPC, which provides encouraging disease control,
reasonable toxicity and affordable ﬁnancial burden.References
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